Pneuma Respiratory, which is developing a digital soft mist inhaler, has announced the appointment of Jay Morgan as Chairman of the Board. Morgan, a former Bayer and Merck executive who has been a member of the board since 2017, will replace Walt Robb as chairman. Robb will remain a member of the board.
In 2018, Pneuma Respiratory announced that it had raised $8.3 million in Series A financing and that Haisco had made a $10 million equity investment in the company to acquire Chinese rights to products developed by Pneuma.
Pneuma CEO and Co-founder Eric Hunter said, “We are honored to have Jay take on the responsibility of chairman. Jay’s contributions as a member of our board have been invaluable, and I look forward to working with him in his role as chairman. I also want to thank Walt Robb for his advice and counsel as chairman, as well as his ongoing commitment to Pneuma as a valued member of the board.”
Morgan commented, “When I joined the board of Pneuma Respiratory, I was impressed by the strength and depth of the organization and the unique capability of the technology. We will continue to build a world-class company delivering a broad range of drugs and formulations through the lungs. I look forward to working with Eric and the team as Chairman to achieve that goal.”
Read the Pneuma Respiratory press release.
